Gilead and Merck Report Successful Phase 2 Results for Investigational Once Weekly HIV Treatment
Gilead and Merck Report Successful Phase 2 Results for Investigational Once Weekly HIV Treatment
Baeten emphasizes the effectiveness of the investigational regimen by stating, “The study showed promising results for maintaining viral suppression in individuals with HIV. The primary outcome at week 48...indicated that the regimen is poised to advance to Phase 3 trials.” This underscores the significance of the trial's findings, highlighting that the treatment not only achieved its primary outcome but also sets the stage for further clinical evaluation in Phase 3 trials, which is a critical step toward potential approval.
Thank you for watching the video, wish you health and happiness!
Subscribe to the channel at: https://goo.gl/iz6xA4
▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬
If you have any questions, please contact us by email: [email protected]
Sincerely thank you!
▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬
Sign up: / @hivaidsprevention
Facebook: / hivaids2024
Twitter: / daubenh
Gmail: [email protected]